Gary Li Ph.D.
Senior Vice President, QED Therapeutics Biopharmaceutical R&D
About this Panelists/Speakers
Dr. Li has over 15 years of drug discovery and translational research experience at both strategic and operational levels. Currently as SVP of Translational Medicine at QED/BridgeBio, he is responsible for translational research and companion diagnostics. Before joining QED, he was Vice President, Head of Oncology Research at Ignyta, a precision oncology company acquired by Roche in 2018. Prior to Ignyta, Dr. Li held various leadership positions at Pfizer and Johnson & Johnson. During his career, he has made key contributions to multiple oncology therapeutics, including axitinib, crizotinib, dacomitinib, palbociclib, lorlatinib and entrectinib.
